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Cancer early detectionMicroRNAs (miRNAs) are small non-coding RNAs that act as master regulators of many cellular processes. The
expression ofmiRNAs is often deregulated in human tumors, causing the alteration ofmolecularmechanisms rel-
evant for cancer progression. Importantly, miRNAs are detectable in the blood and their quantity ﬂuctuations are
the hallmark of pathogenic conditions, including cancer. Several groups reported the identiﬁcation of circulating
cell-free miRNAs (cf-miRNAs) in the human serum and plasma and demonstrated their diagnostic and prognos-
tic utility. Other studies also shown that it may be feasible to apply such cf-miRNA signatures within screening
programs in order to improve cancer early detection. Circulating cf-miRNAs therefore appear to be excellent can-
didates for blood-borne cancer biomarkers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).MicroRNAs (miRNAs) can be isolated from a wide range of different may be indeed delivered to neighboring cells where, following uptake,
tissues and biological specimens, including bioﬂuids. In 2008, pioneer
studies demonstrated that miRNAs were detectable in the plasma and
serum and that they were particular resistant to degradation by RNAses
in the blood (Chen et al., 2008). Subsequent studies reported the
presence of cell-free miRNAs (cf-miRNAs) in virtually all other body
ﬂuids (Weber et al., 2010), and raised several questions regarding the
cf-miRNA stability in the body ﬂuids, the mechanisms of release from
cells, and their biological functions.
Cf-miRNAs were found within microvesicles/exosomes, apoptotic
bodies (AB), HDL structures, or complexedwith AGOproteins (that con-
stitute the miRNA-induced silencing complex, miRISC) (Turchinovich
and Burwinkel, 2012) (Fig. 1), which protect them by the action of
RNAses. Of note, packaging of miRNAs in exosomes can be controlled
by positive selection mechanisms, such as the ceramide-dependent
secretory pathway controlled by the nSMase enzyme (e.g. the ceramide
biosynthesis neutral sphingomyelinase) (Kosaka et al., 2010). However,
how exactly miRNAs are selected and loaded to exosomes, and how the
trafﬁcking is regulated in physiological and pathological conditions, are
not yet understood. Another unmet question is about the biological
function of cf-miRNAs. In cancer cells, the extracellular release of
miRNAs can be a way to reduce the intracellular level of miRNAs with
tumor suppressor functions (Ohshima et al., 2010). On the other hand,
cf-miRNAs can function as a paracrine signal to modify tumor microen-
vironment and support cancer progression; exosomal/MVB/AB-miRNAsSofferenza, Via Cappuccini 1,
).
. This is an open access article underthey can modulate the transcription of target-mRNAs (Turchinovich
and Burwinkel, 2012) (Fig. 1). An intriguingly alternative mechanism
of action for cf-miRNAs was also proposed: the AGO2-complexed miR-
21 and miR-29a may act as signaling molecules via binding to intracel-
lular Toll-like receptors (murine TLR-7 and human TLR-8), which are a
family of receptors characteristic of immune cells involved in the innate
immune system (Fabbri et al., 2012). The activation of immune cells
expressing TLRs stimulates secretion of inﬂammatory cytokines that
ultimately induce tumor cell spread (Fabbri et al., 2012).
Quantities and species of cf-miRNAs were shown to ﬂuctuate in the
presence of malignant and non-malignant disease (Chen et al., 2008).
More recently, we and others proposed a reliable method to identify
and quantify serum/plasma miRNAs starting from low amounts of
serum/plasma (less than 300 μl) that could be easily implemented in
the clinic for lung cancer early diagnosis. Using this method, two
cf-miRNA signatures diagnostic for asymptomatic lung cancer were
validated in high-risk individuals (N55 years of age, smokers) enrolled
in two large Italian lung screening trials (the COSMOS trial, n = 1115
and the MILD trial, n = 939) (Montani et al., 2015; Sozzi et al., 2014).
Despite the fact that these two signatures were derived using different
blood components (i.e., serum or plasma; see further below) and from
different subjects, they have a substantial fraction of overlapping
miRNAs (miR-92a-3p, miR-30c-5p, miR-30b-5p, miR-148a-3p, miR-
140-5p), which further conﬁrms the reliability of cf-miRNAs when
used as cancer biomarkers. Of note, several other cf-miRNA signatures
were recently proposed for the diagnosis of different cancer types
(ovary, breast, prostate, liver, colorectal, brain, melanoma, pancreas,
etc.). It would be interesting to perform a pan-cancer screening study
to understand the ability of these signatures to discriminate amongthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A) Intracellular miRNA processing and function. B) Extracellular release of mature miRNA. C) Modulation of transcription by exogenous miRNA.
5F. Montani, F. Bianchi / EBioMedicine 5 (2016) 4–6different types of cancer; thiswill be relevant for the application of these
signatures in cancer screening programs.
There are a number of reasons that make the possibility to use
blood-based miRNA signatures as diagnostic tools very attractive:
i) cancer can bediagnosed in aminimally invasiveway through a simple
blood test; ii) a blood test does not require hospitalization and the
access to complex and expensive technologies; and iii) blood-based
miRNA tests can preselect high-risk individuals thus increasing the
accuracy of cancer screening programs. Currently, selection criteria forhigh-risk individuals to be enrolled in cancer screening programs are
principally based on epidemiological characteristics, such as age,
smoking status, exposition to asbestos, obesity, presence of chronic
diseases, familial history of cancer, and genetic predisposition to cancer
(i.e. BRCA1/BRCA2 carriers). However, the incidence of cancer in these
high-risk cohorts is dismal. For example, only ~1% of the high-risk
individuals who underwent low-dose computed tomography (LDCT)
screening were diagnosed with lung cancer (Montani et al., 2015),
which limits the widespread application of such screening protocols.
6 F. Montani, F. Bianchi / EBioMedicine 5 (2016) 4–6For this reason, the development of blood-based miRNA tests holds the
potential to increase screening protocol sensitivity and speciﬁcity, while
decreasing other unnecessary and potentially harmful diagnostic proce-
dures (i.e., exposure to ionizing radiations during computed
tomography, or mammography scans).
It is important to note, that almost half of the published cf-miRNA
signatures were discovered analyzing serum samples, while the others
were derived from plasma samples. Cf-miRNAsmay vary in their quan-
tities and species if measured in serum or in plasma samples (Wang
et al., 2012). Therefore, when assessing the overlap among cf-miRNA
signatures in different studies or planning validation–screening studies,
the blood components used to derive these signatures should be taken
into consideration.
It is foreseeable that the molecular analysis of liquid biopsies
(blood, urine, etc.) will become the gold standard for developing non-
invasive diagnostic and prognostic tests. Such tests will not require
hospitalization and could be offered in peripheral health centers,
therefore potentially augmenting the accrual of high-risk individuals
to cancer screening programs. In addition, the possibility to collect
multiple samples from the same patients will deﬁnitely help clinicians
to better monitor therapy response and decide for an optimal
treatment.
However, there are still some methodological limitations that need
to be resolved before the large-scale application of such molecular
tests. For example, the numbers of steps required to obtain andmeasure
circulating nucleic acids are numerous and require expensive and
complex technology. In such scenario, the development of point-of-
care testing (POCT) to measure cf-miRNA directly in the blood (Jin
et al., 2015) is overriding for the application of these next-generation
blood tests in a population-scale. Furthermore, the sensitivity and spec-
iﬁcity of cf-miRNA tests should be improved to augment the detection
rate and avoid false positives and negative results, which are detrimen-
tal for cancer early detection screening programs.
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